Cullinan Oncology, Inc. — FY2021 Form 10-K
Business context and reporting period. The filing is for the fiscal year ended December 31, 2021, not a stand-alone fourth quarter. The registrant’s name in the filing is Cullinan Oncology, Inc. (ticker CGEM); the request metadata uses “Cullinan Therapeutics.” The company is a clinical-stage oncology biopharmaceutical business with three clinical-stage candidates and five preclinical programs. It reported no product sales.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| License revenue | $18.9 million | None |
| Research and development expense | $57.8 million | $43.2 million |
| General and administrative expense | $29.1 million | $17.1 million |
| Net loss | $67.5 million | $59.5 million |
| Net loss attributable to Cullinan common stockholders | $65.6 million | $51.8 million |
| Net loss per share, basic and diluted | $1.52 | $2.60 |
| Net cash used in operating activities | $43.4 million | $29.8 million |
- The $18.9 million revenue was the net upfront license fee from Zai Lab for Greater China rights to CLN-081; it is not recurring product revenue. Potential Zai milestones and royalties had not been earned.
- Operating loss was $68.0 million. A margin comparison is not meaningful because revenue was a one-time license payment and the company had no product sales.
- At year-end, cash and cash equivalents were $59.8 million, short-term investments $230.7 million, and long-term investments $140.4 million—$430.9 million in total cash and investments. Current assets were $296.6 million versus current liabilities of $11.7 million.
- Management said existing cash and investments were expected to fund operations through 2024, based on its operating plan and assumptions. The filing warns actual cash needs may be higher or funding may be needed sooner.
- Net cash provided by financing was $268.8 million, primarily from the January 2021 IPO. Net cash used in investing was $333.8 million, largely reflecting purchases of marketable securities. No debt is reported on the balance sheet; total liabilities were $11.8 million, principally accounts payable and accrued expenses.
- No dividends have been paid or are anticipated in the foreseeable future. The company reported no off-balance-sheet arrangements.
Material changes and notable items
- Revenue rose from zero to $18.9 million, while R&D expense increased 34% and G&A expense increased 70%. Net loss increased about 14% year over year.
- R&D growth primarily reflected higher CLN-081 trial enrollment and manufacturing costs; G&A growth included public-company costs and a $6.7 million non-recurring stock-compensation charge associated with the CEO transition.
- The company completed its IPO in January 2021, raising approximately $264.5 million net. Shares outstanding were 44.3 million at year-end 2021, compared with 29.8 million at year-end 2020.
- FY2021 operating cash use rose to $43.4 million from $29.8 million. The company remained loss-making, with an accumulated deficit of $158.9 million.
- Net loss per share improved to $1.52 from $2.60 despite the larger net loss attributable to common stockholders; the weighted-average share count increased substantially following the reorganization and IPO, so per-share comparisons require context.
Pipeline, outlook, and risks
- CLN-081: In a Phase 1/2a trial for previously treated NSCLC with EGFR exon 20 insertion mutations, the company reported a 39% confirmed response rate at 100 mg twice daily (14 of 36 response-evaluable patients) and disease control (partial response or stable disease) in 35 of 36. The company reported no Grade 3 or higher treatment-related rash or diarrhea at that dose; one Grade 3 pneumonitis case was observed. At 150 mg twice daily, higher-grade diarrhea, rash and liver-enzyme elevations led the company to stop further enrollment. Data were preliminary, with follow-up ongoing. FDA Breakthrough Therapy Designation was granted in January 2022.
- CLN-049 and CLN-619: Phase 1 trials began in late 2021 for relapsed/refractory AML and advanced solid tumors, respectively. The filing described these programs as early clinical development; it did not provide clinical efficacy results.
- Development plans: Management intended to provide a CLN-081 regulatory update by the end of Q1 2022, clinical updates for CLN-049 and CLN-619 by mid-2023, and submit INDs for CLN-617 and CLN-978 by the end of the first half of 2023. These are forward-looking plans, not guarantees.
- The company expects continued operating losses and substantial R&D spending. Its ability to progress depends on clinical results, patient enrollment, regulatory decisions, financing, intellectual-property protection, and third-party research, trial and manufacturing providers.
- Key risks include clinical failure or adverse effects, enrollment delays, competition, reliance on external manufacturers and CROs, COVID-19 disruption, uncertain reimbursement and commercialization, and potential dilution or loss of control in subsidiaries. CLN-081’s reported efficacy and safety results are preliminary and may change with additional data.
- KPMG issued an unqualified audit opinion. Management concluded disclosure controls were effective at the reasonable-assurance level; the filing did not include management’s assessment or auditor attestation on internal control over financial reporting because of the newly public company transition period.
Important facts for investors to verify
- Review the full audited financial statements and notes, including the investment portfolio, accrued R&D costs, subsidiary ownership and noncontrolling-interest accounting.
- Confirm the final CLN-081 efficacy and safety dataset, dose selection, FDA feedback, and any subsequent regulatory or trial developments; distinguish preliminary December 2021 data from later confirmed results.
- Track whether the stated 2022–2023 development milestones were achieved and whether the cash runway remains consistent with management’s assumptions.
- Assess the terms and economics of subsidiary and licensing arrangements, including Taiho obligations, Zai milestones and royalties, and potential dilution from subsidiary financing.
- Monitor clinical enrollment, manufacturing supply, intellectual-property protection, and the company’s ability to finance its pipeline without materially diluting shareholders.